Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial Article

sustainable development goals

publication date

  • June 10, 2024

webpage

published in

start page

  • 582

end page

  • 593

volume

  • 81

issue

  • 6